Efficiency of subconjunctival bevacizumab on pterygium
Abstract
Background: To evaluate the effect and complications of subconjunctival bevacizumab (Avastin ®) on primary and recurrent pterygium. Methods: This prospective study included sixteen patients with pterygium, who received subconjunctival injection of bevacizumab (1.25 mg/0,1 mL). Digital photography was used to evaluate vascularization of pterygium at 1 week, 1 month and 6 months after injection. Results: Sixteen patients (9 men and 7 women), aged between 41 and 74 years, with pterygium were included in the study. The pterygium was primary in nine patients and recurrent in seven patients. A rapid regression of vascularisation of pterygium was noted one week after treatment in all patients treated with bevacizumab. The recurrence was observed in two patients 1 month and in ten patients 6 months after injection. No change of visual acuity was noted and no systemic or ocular adverse events were observed. Conclusions: Subconjunctival bevacizumab (Avastin®) was safe and effective in providing a short-term regression of conjunctival vessels in the pterygial bed.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
